Log In
CQMS
Make a Donation
Log In
Donate
DONATE OR FUNDRAISE
Donate
Read Angelo's story about taking part in our kidney cancer trial
Sign up now to join our Km's for Cancer Research Challenge in October
Submit your trial idea now for our 2026 Concept Development Workshop
Submit your abstract for our 2027 Annual Scientific Meeting, Hobart, 9-12 March 2027.
TROG receives $2.86m MRFF grant for new breast cancer trial

TROG 92.01 – PCNSL (Phase II)

Completed
Lymphoma

A Phase II Study of Intravenous Methotrexate and Cranial Irradiation in the Treatment of Primary Central Nervous System Lymphoma (PCNSL)

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)
Prev Post

TROG 94.01/AGITG IG9401 – Oesophagus – Localised Resectable (IG9401)

Next Post

TROG 91.01 – Head & Neck – Accelerated RT

Related Post

17 September, 2026

Meet the TROG Quality Assurance team

TROG UPDATES: 17 September 2026 Our Quality Assurance team

17 September, 2026

TROG trial of new lung cancer radiation therapy approach opens

LATEST NEWS: 17 September 2026 The first Australian site